1. Home
  2. XGN vs RFL Comparison

XGN vs RFL Comparison

Compare XGN & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XGN
  • RFL
  • Stock Information
  • Founded
  • XGN 2002
  • RFL 2017
  • Country
  • XGN United States
  • RFL United States
  • Employees
  • XGN N/A
  • RFL N/A
  • Industry
  • XGN Medical Specialities
  • RFL Real Estate
  • Sector
  • XGN Health Care
  • RFL Finance
  • Exchange
  • XGN Nasdaq
  • RFL Nasdaq
  • Market Cap
  • XGN 72.3M
  • RFL 55.3M
  • IPO Year
  • XGN 2019
  • RFL N/A
  • Fundamental
  • Price
  • XGN $5.15
  • RFL $1.92
  • Analyst Decision
  • XGN Buy
  • RFL
  • Analyst Count
  • XGN 1
  • RFL 0
  • Target Price
  • XGN $7.00
  • RFL N/A
  • AVG Volume (30 Days)
  • XGN 163.8K
  • RFL 27.8K
  • Earning Date
  • XGN 11-12-2024
  • RFL 12-27-2024
  • Dividend Yield
  • XGN N/A
  • RFL N/A
  • EPS Growth
  • XGN N/A
  • RFL N/A
  • EPS
  • XGN N/A
  • RFL N/A
  • Revenue
  • XGN $55,751,000.00
  • RFL $697,000.00
  • Revenue This Year
  • XGN $6.74
  • RFL N/A
  • Revenue Next Year
  • XGN $17.32
  • RFL N/A
  • P/E Ratio
  • XGN N/A
  • RFL N/A
  • Revenue Growth
  • XGN 8.00
  • RFL 151.62
  • 52 Week Low
  • XGN $1.30
  • RFL $1.29
  • 52 Week High
  • XGN $6.22
  • RFL $2.50
  • Technical
  • Relative Strength Index (RSI)
  • XGN 58.53
  • RFL 53.58
  • Support Level
  • XGN $4.71
  • RFL $1.71
  • Resistance Level
  • XGN $6.22
  • RFL $1.92
  • Average True Range (ATR)
  • XGN 0.55
  • RFL 0.10
  • MACD
  • XGN -0.02
  • RFL -0.00
  • Stochastic Oscillator
  • XGN 46.23
  • RFL 84.00

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

Share on Social Networks: